{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:24:24Z","timestamp":1778585064253,"version":"3.51.4"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:p>The wider availability of dolutegravir (DTG) containing HIV therapy for patients living with multidrug-resistant TB (MDR-TB) presents several advantages. DTG-based antiretroviral therapy (ART) has superior potency, reduces pill burden, and may reduce overall treatment-related toxicity,\n giving it the potential to improve outcomes in both diseases. While the uptake of DTG-based ART in programs where drug-resistant TB is treated remains unknown, there is early evidence from three programs that uptake is increasing. The use of DTG-based ART should be scaled-up, beginning with\n antiretroviral-na\u00efve or virologically suppressed patients initiating MDR-TB treatment.<\/jats:p>","DOI":"10.5588\/ijtld.21.0125","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T09:54:00Z","timestamp":1637574840000},"page":"696-700","source":"Crossref","is-referenced-by-count":3,"title":["Expanding the use of dolutegravir-based antiretroviral therapy in multidrug-resistant TB"],"prefix":"10.5588","volume":"25","author":[{"given":"R. A.","family":"Murphy","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Lundquist Institute for Biomedical Innovation at Harbor\u2013UCLA Medical Center, Torrance, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Douglas-Jones","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res (MSF), Khayelitsha, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mucinya","sequence":"additional","affiliation":[{"name":"MSF, Kinshasa, Democratic Republic of the Congo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Sunpath","sequence":"additional","affiliation":[{"name":"University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Govender","sequence":"additional","affiliation":[{"name":"King Dinizulu Hospital Centre, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2021\/00000025\/00000009\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T09:54:06Z","timestamp":1637574846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.21.0125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"alternative-id":["1027-3719(20210901)25:9L.696;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.21.0125","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}